Every year there are 'winners' and 'losers' from the biggest confab around oncology of the year.
These equities have been in rally mode since April.
These names are moving up or down in a big way ahead of releasing drug-trial results.
American Society of Clinical Oncology will see presentations from dozens of companies.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Loxo Oncology, Inc , where a total volume of 2,775 contracts has been traded thus far today, a contract volume which is representative of approximately 277,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 85.6% of LOXO's average daily trading volume over the past month, of 324,305 shares.
The most recent short interest data has been released for the 12/29/2017 settlement date, which shows a 445,280 share increase in total short interest for Loxo Oncology, Inc , to 4,463,652, an increase of 11.08% since 12/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Jim Cramer highlights Nucor, Henry Schein, Kemet, Splunk, and Loxo Oncology.
Jim Cramer says this is the 'Era of Good Feelings,' the week when despite the bad news, buyers still want to buy and it feels like there's a ban on selling.
